BioNJ Hosts Its Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition – Yahoo Finance

(Click here for a photo gallery from the competition)
Updated December 7, 2022
TRENTON, N.J., Dec. 7, 2022 /PRNewswire/ — BioNJ, New Jersey’s life sciences trade association, hosted an Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition on Saturday, December 3, at Rutgers Business School. BioNJ’s Business Plan Case Competition, which is part of a broader BioNJ strategic initiative of Health Equity in Clinical Trials, was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity.
BioNJ believes that health equity in clinical trials is critical to deepening the understanding of the safety and efficacy of medicines in under-represented populations, expanding access to medical innovation for these populations and increasing dialogue and trust among the biopharma industry, communities and healthcare systems. By discovering new approaches, utilizing new technologies and developing new business standards to make trials more accessible, we can work to create more agile, efficient and Patient-centered medical research.
Eight teams, competing for more than $20,000 in prize money, were tasked with developing a business plan defining a new solution, application or technology to help address this important and challenging problem. Teams identified one particular type of health disparity on which to frame their proposed solutions and connected with community-based organizations to better understand the real-world barriers that exist for their chosen populations to engage in clinical trials. The disease areas on which the respective teams focused included Alzheimer’s, heart failure, multiple sclerosis, diabetes type 1 and type 2, colorectal and cervical cancers, and oncology.
Each team was comprised of 4-5 diverse, cross-disciplinary students from MBA and other allied graduate programs. (Click here to review the resumes of our teams.)
Baylor College of Medicine, Northwestern University & Rice University
Columbia University
Johns Hopkins University
Rutgers University
Temple University
Tuck School of Business at Dartmouth
University of Arkansas at Pine Bluff
University of Pittsburgh
“There is an urgent need to bring more diversity to clinical trials in order to better serve Patients and their communities…thereby helping to address health inequities,” said Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs for Bristol Myers Squibb; BioNJ Board Member and Chair of the BioNJ Health Equity in Clinical Trials Initiative. “Only by improving diversity in clinical trials will we be able to deepen our understanding of the safety and efficacy of medicines for all populations. I am extremely proud of our teams. Each of the business plans offered a unique out-of-the-box solution – helping advance our ambition to have no Patient left behind.”
Live pitch presentations were made throughout the day to a Panel of Judges comprised of industry experts:
Naikia Atkinson, Director, U.S. Clinical Trials Diversity and Inclusion, Sanofi
Schylr Greggs, Director, Technology Operations, Medidata
Sharon Hanlon, Head, Clinical Trial Engagement & Enrollment, Bristol Myers Squibb
Maribel Hernandez, Vice President, Clinical Operations & Special Projects, PTC Therapeutics
Jack Rosenberg, Manager, Investments and Business Development, TrialSpark
Del Smith, Co-Founder & CEO, Acclinate
Lolita Smith, Program Manager, Rare Disease Diversity Coalition, Black Women’s Health Imperative
Matt Walz, CEO, TrialBee
“Although ultimately three winning teams were presented with cash prizes, each team has made a difference for Patients by offering new solutions and technologies to better serve Patients, build community trust and address gaps in health care delivery,” said Paul Howard, Ph.D., BioNJ Business Case Competition Steering Committee Chair and Senior Director, Public Policy for Amicus Therapeutics. “This is just the start as we work to share these proposals more broadly.”
A white paper with all of the presentations will be published in April and rolled out during BioNJ’s acclaimed BioPartnering Conference – which brings together more than 500 industry professionals from around the globe. The three winning teams will present their plans during the April 18 BioPartnering Conference and all of the students are invited to attend to meet the community.
Winning teams include:
First Place: Johns Hopkins University ($10,000) who focused their plan on increasing representation in clinical trials for the treatment of Alzheimer’s Disease through community engagement strategies and the use of digital tools.
Second Place: Rutgers University ($7,000) who focused their plan on using population health and real-world data analytics to calculate health equity targets specific to clinical trial sites in prostate cancer.
Third Place: Baylor College of Medicine, Northwestern University & Rice University ($3,500) who focused their plan on increasing Hispanic/Latinx involvement in clinical trials by training community healthcare workers from refugee and immigrant populations.
“BioNJ’s mission is to help our Members help Patients. It is with the vision of Health Equity for all that BioNJ launched our Health Equity in Clinical Trials Strategic Initiative, of which the MBA Business Plan Competition is one of three important workstreams,” said BioNJ President and CEO, Debbie Hart. “In addition to thanking our extraordinary teams for their commitment and time, I’d like to thank our Steering Committee; industry supporters, including Bristol Myers Squibb, Medidata, Amicus Therapeutics, PTC Therapeutics, Sanofi, Insmed, PsychoGenics, Thermo Fisher Scientific, Crowley Law and the Rare Disease Diversity Coalition; our expert judges and our colleagues from the Kith Collective. It was only with their guidance and support that we have been able to bring this important initiative forward.”
For more information, please visit BioNJ.org/Health-Equity-Clinical-Trials.
About BioNJ
BioNJ is the life sciences trade association for New Jersey, representing close to 400 research-based life sciences organizations and stakeholders across the healthcare ecosystem from the largest biopharmaceutical companies to early stage start-ups for nearly 30 years. Because Patients Can’t Wait®, BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients Have Access to Lifesaving Medicines.
Recognized as a respected thought leader, an influential advocate and a sought-after convener of the life sciences industry, BioNJ works directly with legislative leaders in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation and ensure health equity and healthcare affordability. With innovation as the driving force behind medical breakthroughs, BioNJ’s mission is to help our Members help Patients by providing transformative resources, including access to government and industry leaders, capital and State incentives, timely educational programs, skilled talent and a value-driven purchasing program.
BioNJ is inspired by and privileged to work with those committed to improving the lives of Patients and their families around the world. For more information visit www.BioNJ.org.
Media Contact
Randi Bromberg
Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067
RBromberg@BioNJ.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/bionj-hosts-its-inaugural-health-equity-in-clinical-trials-mba-business-plan-case-competition-301697256.html
SOURCE BioNJ
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK). On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.
Prometheus Bio reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted higher.
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective. Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.
The company focuses on therapies to treat chronic debilitating conditions and after the market closed on Monday, it released phase 2 trial results for its lead therapy, NE3107, to treat Alzheimer's disease and Parkinson's disease. The therapy was more effective (6 points) higher when used on Parkinson's patients who were under 70. BioVie also tested NE3107 as a monotherapy in mild Alzheimer's patients and said patients showed 2.1 points of improvement in enhanced cognition on the modified Alzheimer's Disease Assessment Scale (ADAS).
The vaccine from Japanese drugmaker Takeda will provide an alternative to a Sanofi vaccine that has been dogged by safety issues.
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
If so, you should know that investors like you found what they were looking for this year in the biotechnology and medical technology spaces. Shares of Belite Bio (NASDAQ: BLTE) are up about 209% this year. Investors have been piling into this clinical-stage biotechnology company thanks to encouraging early results from its lead candidate, LBS-008.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Eating less ultra-processed foods can help maintain a healthy heart and slow down cognitive decline. Doctor Pradeep Kumar, from Austin Gastroenterology, joins us with more.
The EU Health Commissioner will on Friday propose extending the deadline for companies to comply with a new law regulating medical devices, she told Reuters on Thursday as doctors warn the legislation is causing shortages of lifesaving equipment. Stella Kyriakides told Reuters that challenges in implementing the law were threatening supplies of critical devices, such as catheters used for surgeries on newborns with heart conditions. "This is why, to mitigate any short-term risks, we will tomorrow announce an extension of the transition period to mitigate any risk of shortages."
Drugmakers GSK Plc, Pfizer Inc, Sanofi SA and Boehringer Ingelheim on Tuesday were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science. The ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court, though it does not directly affect tens of thousands of similar cases pending in state courts around the country. "We are extremely surprised by this miscarriage of justice," and "fully expect" the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement.
Fauci criticizes an "extreme" ideological divide that he said has led to a disproportionate amount of Covid deaths among Republicans compared to Democrats.
It could become the first approved RSV vaccine in the U.S. for older adults who are at risk of the lung disease. Pfizer's application to the FDA is supported by data from a late-stage study in which the vaccine was found safe and effective.
Patients considering LASIK surgery should be warned that they may be left with double vision, dry eyes, difficulty driving at night and, in rare cases, persistent eye pain, according to draft guidance by the Food and Drug Administration. After surgery, patients might still need eyeglasses, the document warns. If put into effect, the agency’s warnings are likely to come as a surprise to many Americans, who view the procedure as safe and commonplace. Every year, more than half a million adults und
Singer shared news in tearful Instagram video
Eli Lilly And Co (NYSE: LLY) announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer. The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up. Also read: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage. In 2020, The monarchE trial hit statistical significance after a median o
Photo Illustration by Luis G. Rendon/The Daily Beast/Getty ImagesTaylor Dayne remembers meeting Kirstie Alley about 25 years ago at a Super Bowl party in Florida and the pair becoming instant friends.“She was just so funny, exuberant, full of life. She was like, ‘Come back to my house.’ I think we were in Tampa. I really loved that woman,” the musician told The Daily Beast. “She was a truly lovely, beautiful human being who brought a lot of joy and a lot of fun and a lot of happiness and was ver
Actress Kirstie Alley died of colon cancer. Dr. Bidhan Das, a Colorectal surgeon with UTHealth Houston and UT Physicians, discusses the symptoms of colon cancer and why is it on the rise among younger patients.

source

brucemeyernet

Learn More →

Leave a Reply

Your email address will not be published. Required fields are marked *